COMMUNIQUÉS West-GlobeNewswire

Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
03/12/2018
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq [...]
Diversicare Completes Sale of Three Skilled Nursing Facilities in Kentucky
03/12/2018
BRENTWOOD, Tenn., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Diversicare Healthcare Services, Inc. (NASDAQ: DVCR), a premier provider of post-acute care services, today announced that effective December 1, 2018 the Company [...]
Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
03/12/2018
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/12/2018
EMERYVILLE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]
Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
03/12/2018
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth [...]
Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®
03/12/2018
CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to [...]
Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
03/12/2018
BOSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today [...]
University Medical Centre Groningen chooses TAT-5000 of Exergen Medical as standard thermometer throughout hospital
03/12/2018
WATERTOWN, Mass. and GRONINGEN, The Netherlands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- University Medical Centre Groningen has decided to standardize on the TAT-5000 thermometer of Exergen Medical. The well-known university [...]
Nextech and Red Spot Interactive Partner to Enhance Provider Retention and Patient Acquisition
03/12/2018
Product integration delivers tools to encourage profit driven business decisions for specialty healthcare practices TAMPA, Fla., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nextech Systems , a leading provider of healthcare [...]
INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018
03/12/2018
INNATE PHARMA ANNOUNCES UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2018 ANNUAL MEETING Differentiating profile of IPH4102 confirmed: [...]
INNATE PHARMA : ASH, présentation de résultats d'IPH4102 chez les patients présentant un syndrome de Sézary réfractaire et poursuite du développement en phase II dans les lymphomes de type T
03/12/2018
CONGRÈS ANNUEL DE LA SOCIÉTÉ AMERICAINE D'HÉMATOLOGIE (ASH) 2018 : PRÉSENTATION DE NOUVEAUX RÉSULTATS D'IPH4102 CHEZ LES PATIENTS PRÉSENTANT UN SYNDROME DE SÉZARY RÉFRACTAIRE ET POURSUITE DU DÉVELOPPEMENT EN PHASE II [...]
BeiGene Presents Clinical Results of Tislelizumab in Relapsed/Refractory Classical Hodgkin’s Lymphoma at the 60th American Society of Hematology Annual Meeting
03/12/2018
Company to Host Investor Meeting and Webcast Today, December 3, at 8 pm PST BEIJING, China and CAMBRIDGE, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage [...]
Hybrigenics (ALHYG) : Moonstone Investments a soumis une proposition de transaction, sous conditions suspensives.
03/12/2018
C ette proposition, crédible et créatrice de valeur, vise à donner un nouvel espoir à la société Hybrigenics et ses actionnaires et constitue une alternative à la dissolution anticipée. Amsterdam, le 3 décembre 2018 Le [...]
CAPS® Teams with Kit Check to Add Serialized Radio Frequency Identification (RFID) Tags on Pre-Filled Syringes
03/12/2018
BETHLEHEM, Pa., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Central Admixture Pharmacy Services, Inc. (CAPS) has announced a collaborative agreement to embed Kit Check’s serialized RFID tags on CAPS’ pre-filled anesthesia [...]
Exeter Hospital joins North American Partners in Anesthesia
03/12/2018
MELVILLE, N.Y., Dec. 03, 2018 (GLOBE NEWSWIRE) -- North American Partners in Anesthesia (NAPA) , one of the leading single-specialty anesthesia and perioperative management companies in the US, recently expanded [...]
Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
03/12/2018
- New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) - CAD patients treated with APL-2 had an improvement in [...]
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
03/12/2018
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO, Switzerland and San [...]
NICOX : Number of voting rights as of November 30. 2018
03/12/2018
Nicox SA Société anonyme with a registered capital of € 29,715,320 Head Office: DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On December 3, 2018, MONTHLY PUBLICATION OF THE [...]
NICOX : Nombre de droits de vote au 30 novembre 2018
03/12/2018
Nicox SA Société anonyme au capital de 29 715 320 euros Siège social : DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 Le 3 décembre 2018, PUBLICATION MENSUELLE DU NOMBRE D' [...]

Pages